{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-002104","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2022-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.668425+00:00","generated_at":"2026-06-27T17:00:45.096762+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Brooklyn ImmunoTherapeutics appoints Heather B. Redman and Erin S. Enright to board","bullets":["Board expanded from 5 to 6; Redman and Enright appointed Jan 14, 2022.","Redman is Managing Partner at Flying Fish Partners; Enright is Managing Member at Prettybrook Partners.","Each received option for 67,000 shares of common stock under 2020 Plan, vesting over 3 years.","Redman joins Compensation and Nominating/Governance Committees; Enright chairs Audit Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-002104","json":"https://secwatch.observer/filing/0001140361-22-002104.json","markdown":"https://secwatch.observer/filing/0001140361-22-002104.md","text":"https://secwatch.observer/filing/0001140361-22-002104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036122002104/0001140361-22-002104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036122002104/brhc10032872_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T17:00:45.096762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29164103bb","claim":"Erin S. Enright was appointed as Director at Ernexa Therapeutics Inc..","evidence_excerpt":"On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122002104/0001140361-22-002104-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cfdfd69cb0","claim":"Heather B. Redman was appointed as Director at Ernexa Therapeutics Inc..","evidence_excerpt":"On January 14, 2022, the board of directors (the “Board”) of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), expanded its size from five to six directors and appointed Heather B. Redman and Erin S. Enright as new directors with immediate effect to fill the existing vacancy on the Board and the new vacancy resulting from the increase in the Board’s size.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122002104/0001140361-22-002104-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}